Live Earnings Conference Call: Dare Bioscience will host a live Q3 2026 earnings call on November 16, 2026 at 4:30PM ET. Follow this link to get details and listen to Dare Bioscience's Q3 2026 earnings call when it goes live. Get details. NASDAQ:DARE Dare Bioscience (DARE) Stock Price, News & Analysis $0.66 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$0.64 -0.02 (-3.41%) As of 11/13/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Dare Bioscience Stock (NASDAQ:DARE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dare Bioscience alerts:Sign Up Key Stats Today's Range$0.63▼$0.7050-Day Range$0.62▼$0.8552-Week Range$0.61▼$3.78Volume73,872 shsAverage Volume148,890 shsMarket Capitalization$12.93 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingModerate Buy Company Overview Daré Bioscience is a clinical-stage biopharmaceutical company focused on developing therapies and products for women’s health. Its work spans areas including contraception, vaginal health and sexual health, with an emphasis on addressing conditions and needs that have had limited treatment options. The company’s product candidates include Ovaprene, a hormone-free, monthly-use vaginal contraceptive, and investigational treatments for conditions such as female sexual arousal disorder. These candidates remain in development and are not approved for general use. Daré’s XACIATO, a vaginal gel for bacterial vaginosis, received U.S. Food and Drug Administration approval in 2021; the company later licensed commercialization rights to Organon. Daré is based in San Diego, California, and its leadership includes President and Chief Executive Officer Sabrina Martucci Johnson.AI Generated. May Contain Errors. Read More Dare Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreDARE MarketRank™: 3.161638782765 of 5 starsDare Bioscience scored higher than 63% of companies evaluated by MarketBeat, and ranked 312th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingDare Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDare Bioscience has a consensus price target of $5.00, representing about 660.6% upside from its current price of $0.66.Amount of Analyst CoverageDare Bioscience has only been the subject of 4 research reports in the past 90 days.Read more about Dare Bioscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dare Bioscience are expected to grow in the coming year, from ($0.74) to ($0.51) per share.Price to Book Value per Share RatioDare Bioscience has a P/B Ratio of 3.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dare Bioscience's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.19% of the float of Dare Bioscience has been sold short.Short Interest Ratio / Days to CoverDare Bioscience has a short interest ratio ("days to cover") of 6.07.Change versus previous monthShort interest in Dare Bioscience has recently decreased by 13.78%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDare Bioscience does not currently pay a dividend.Dividend GrowthDare Bioscience does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.42 News SentimentDare Bioscience has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Dare Bioscience this week, compared to 3 articles on an average week.Search Interest4 people have searched for DARE on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Dare Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dare Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders3.40% of the stock of Dare Bioscience is held by insiders.Percentage Held by Institutions6.70% of the stock of Dare Bioscience is held by institutions.Read more about Dare Bioscience's insider trading history. Receive DARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dare Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DARE Stock News HeadlinesDare Bioscience Expands Product Launches as Contraceptive and HPV Trial Data ApproachNovember 14 at 2:00 AM | americanbankingnews.comDare Bioscience (DARE) Expected to Release Earnings on ThursdayNovember 11, 2026 | americanbankingnews.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected. | Porter & Company (Ad)Daré Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026November 10, 2026 | globenewswire.comDaré Bioscience Releases Next Episode in “CEO Corner” Video SeriesNovember 9, 2026 | globenewswire.comDaré Bioscience to Present at Stifel’s 2026 Healthcare ConferenceNovember 4, 2026 | finance.yahoo.comDaré Bioscience to Present at Stifel's 2026 Healthcare ConferenceNovember 4, 2026 | globenewswire.comDaré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains MomentumOctober 30, 2026 | globenewswire.comSee More Headlines DARE Stock Analysis - Frequently Asked Questions How have DARE shares performed this year? Dare Bioscience's stock was trading at $1.93 at the beginning of the year. Since then, DARE stock has decreased by 65.9% and is now trading at $0.6574. How were Dare Bioscience's earnings last quarter? Dare Bioscience, Inc. (NASDAQ:DARE) posted its quarterly earnings results on Thursday, August, 13th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.10. The biotechnology company earned $187.55 thousand during the quarter, compared to analysts' expectations of $2 thousand. Dare Bioscience had a negative net margin of 803.80% and a negative trailing twelve-month return on equity of 748.30%. Read the conference call transcript. When did Dare Bioscience's stock split? Dare Bioscience's stock reverse split before market open on Monday, July 1st 2024.The 1-12 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Dare Bioscience IPO? Dare Bioscience (DARE) raised $102 million in an initial public offering on Thursday, April 10th 2014. The company issued 8,500,000 shares at $11.00-$13.00 per share. Who are Dare Bioscience's major shareholders? Dare Bioscience's top institutional investors include State Street Corp (0.24%). View institutional ownership trends. How do I buy shares of Dare Bioscience? Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dare Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dare Bioscience investors own include Tonix Pharmaceuticals (TNXP), Tesla (TSLA), Bionano Genomics (BNGO), Gevo (GEVO), Ideanomics (IDEX), NIO (NIO) and Matinas Biopharma (MTNB). Company Calendar Last Earnings8/13/2026Today11/15/2026Next Earnings (Estimated)11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 DARE's financial health is in the Red zone, according to TradeSmith. DARE has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DARE CIK1401914 Webwww.darebioscience.com Phone(858) 926-7655Fax617-494-1544Employees24Year Founded2006Price Target and Rating Average Price Target for Dare Bioscience$5.00 High Price Target$12.00 Low Price Target$1.00 Potential Upside/Downside+660.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.40 million Net Margins-803.80% Pretax Margin-803.80% Return on Equity-748.30% Return on Assets-38.75% Debt Debt-to-Equity RatioN/A Current Ratio0.99 Quick Ratio0.99 Sales & Book Value Annual Sales$1.03 million Price / Sales12.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book3.29Miscellaneous Outstanding Shares19,670,000Free Float19,000,000Market Cap$12.93 million OptionableNot Optionable Beta1.11 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:DARE) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredReport: OCC clears Trump-linked bankI told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was. Federal r...Crypto 101 Media | SponsoredGlobal Industrial Powerhouse Taps Nasdaq Drone MicrocapA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dare Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dare Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.